CYP3A4 and COVID-19: NIH guidelines recommend ritonavir-boosted nirmatrelvir for nonhospitalized patients with COVID-19 who are at high risk of progressing to severe disease.23 Ritonavir, a well-known perpetrator, is a P-gp inhibitor and a strong CYP3A4 inhibitor.